Evidence map›Paper›PMID 37661840›Full record

ArticleThe journal of pathology. Clinical research2023

Digital image analysis allows objective stratification of patients with silent PIT1-lineage pituitary neuroendocrine tumors.

Jiangyan Zhao, Chenxing Ji, Haixia Cheng, Zhen Ye, Boyuan Yao, Ming Shen, Xuefei Shou, Xiang Zhou, Hongying Ye, Zhaoyun Zhang and 7 more

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Jiangyan ZhaoDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Chenxing JiDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Haixia ChengDepartment of Pathology, Huashan Hospital, Shanghai, PR China.
Zhen YeDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Boyuan YaoFudan University Graduate School, Shanghai, PR China.
Ming ShenDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Xuefei ShouDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Xiang ZhouDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Hongying YeDepartment of Endocrinology, Huashan Hospital, Shanghai, PR China.
Zhaoyun ZhangDepartment of Endocrinology, Huashan Hospital, Shanghai, PR China.
Hong ChenDepartment of Pathology, Huashan Hospital, Shanghai, PR China.
Yongfei WangDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Fuchu HeDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Yao ZhaoDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Wei GongDepartment of Endocrinology, Huashan Hospital, Shanghai, PR China.
Qilin ZhangDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.
Nidan QiaoDepartment of Neurosurgery, Huashan Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, PR China.ORCID 0000-0001-5478-3555
Fudan University · CNHuashan Hospital · CN

Funding

CAMS Innovation Fund for Medical Sciences 2021-I2M-C&T-A-025National Natural Science Foundation of China 82073640National Natural Science Foundation of China U21A20389
6 · The paper itself

Abstract

Studies describing the clinical presentation and prognosis of patients with silent PIT1 (pituitary specific transcription factor)-lineage pituitary neuroendocrine tumors (PitNETs) are rare. We identified patients with positive PIT1 tumor staining but without evidence of hormone hypersecretion at a tertiary center. Clusters were obtained according to cell morphology and immunostaining from each patient's digitally segmented whole slide image. We compared the clinical presentations, radiological features, and prognoses of the different clusters. We identified 146 patients (68 male, 42.9 ± 14.1 years old) with silent PIT1-lineage PitNETs. Morphology clustering suggested that tumors with large nuclei and apparent eccentricity were associated with a higher proportion of aggressiveness and a higher hazard of recurrence [hazard ratio (HR): 2.64, (95% CI, 1.06-6.55), p = 0.037]. Immunohistochemical clustering suggested that tumors with thyroid stimulating hormone (TSH) staining or all negative PIT1-lineage hormones were associated with a higher proportion of aggressiveness and a higher risk of recurrence [HR: 12.4, (95% CI, 1.60-93.5), p = 0.015]. We obtained three-tier risk profiles by combining morphological and immunohistochemical clustering. Patients with the high-risk profile presented the highest recurrence rate compared with those in the medium-risk and low-risk profiles [HR: 3.54, (95% CI, 1.40-8.93), p = 0.002]. In conclusion, digital image analysis based on cell morphology and immunohistochemical staining allows objective stratification of patients with silent PIT1-lineage tumors. Typical morphological characteristics of high-risk tumors are large tumor nuclei and high eccentricity, and typical immunostaining characteristics are TSH staining or negative staining for all PIT1-lineage hormones.

Indexed as

Biomarkers, TumorImage Interpretation, Computer-AssistedNeuroendocrine TumorsPituitary NeoplasmsTranscription Factor Pit-1AdultAgedCell LineageFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesBiomarkers, TumorPOU1F1 protein, humanTranscription Factor Pit-1artificial intelligenceclusteringnonfunctioningpituitary adenoma

Identifiers

PMID37661840
PMCPMC10556262
OpenAlexW4386407280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.